What Is GDUFA Self-Identification Services?
The Generic Drug User Fee Amendments (GDUFA) were established by the FDA to improve the efficiency,safety, and oversight of the generic drug supply chain. As part of this initiative, certain facilities and sites arerequired to self-identify annually with the FDA.
Self-identification serves several critical purposes:
Enables the FDA to maintain an up-to-date inventory of global facilities
Determines annual user fees for API and FDF manufacturers
Helps prioritize risk-based inspections by the FDA
Is mandatory for facilities referenced in any generic drug submission
Failure to self-identify accurately and on time may result in penalties, regulatory delays, or exclusion from ANDA filings.
Why Is GDUFA Self-Identification Services Important?
Submission Prerequisite:
Your facility must be listed in the FDA’s database before it can be referenced in an Abbreviated New Drug Application (ANDA).
Avoid FDA Withholding:
The FDA may refuse to receive ANDAs or delay inspections if required facilities are not properly identified.
Fee Calculation:
Annual facility fees (FDF/API) are directly tied to self-identification status.
Enforcement Risk:
Non-compliance can lead to warning letters, import alerts, and reputational damage.
Process Flow for GDUFA Self-Identification Services
Designation and Notification Filing
We file U.S. Agent information accurately in FDA databases (CDER Direct or ESG portals) and ensure it’s linked to your establishment registration.
FDA Contact Management
We act as your ongoing FDA contact—handling communications, documentation requests, and inspection notices.
Inspection & Compliance Alerting
If an inspection is announced or triggered, we notify you promptly, help interpret the scope, and support compliance coordination.
Annual Update & Renewal Monitoring
We monitor registration renewal timelines and update your FDA records to maintain active status.
Emergency Communications
Should FDA require urgent action (e.g., recalls, alerts), we facilitate immediate response coordination.
How Can We Help in GDUFA Self-Identification Services?
Regulatory Expertise: Our team consists of seasoned professionals with extensive knowledge of GDUFA mandates and FDA submission systems.
Risk-Free Accuracy: We eliminate submission errors that can trigger costly penalties or delay your operations.
Global Facility Support: Whether your site is U.S.-based or international, we navigate regional nuances with precision.
Time-Sensitive Delivery: We manage your timeline to ensure your submission is completed before critical FDA deadlines.
Who Needs a GDUFA Self-Identification Services?
If your site is referenced in an ANDA or supports any stage of the generic drug lifecycle, FDA self-identification is mandatory.
Regulatory Requirements for GDUFA Self-Identification Services
Documents
To complete your submission accurately, the following information and documents are typically required:
- Facility Information: Legal entity name, site name, address, and contact details
- DUNS Number: A valid Dun & Bradstreet identifier for each physical location
- Establishment Type: API, FDF, BE/BA testing, packaging, etc.
- FDA FEI (if available): Facility Establishment Identifier
- Ownership Details: For cross-checking facility relationships
- Contact Person Authorization: Name and role of the person submitting the self-ID
- ANDA Reference (if applicable): Submissions linked to your facility
Cliniexperts assists in gathering and validating these records to prevent data mismatches and delays.
Timeline
Timeline
GDUFA self-identification follows a fixed annual cycle, aligned with the U.S. government’s fiscal year:
- Submission Window: May 1 to June 30 (prior to each fiscal year)
- Effective Period: October 1 to September 30 of the following year
- ANDA Submission Dependency: Your site must be self-identified before it can be listed in an ANDA.
Cliniexperts monitors all relevant deadlines to ensure your submission is filed well before cutoff dates — minimizing risk and ensuringuninterrupted regulatory engagement.
Regulatory Body
U.S. Food and Drug Administration (FDA)
Fees
Self-identification is a prerequisite for being assessed GDUFA facility fees. These fees are charged annually based on your facility type:
- Finished Dosage Form (FDF) Facility Fee
- Active Pharmaceutical Ingredient (API) Facility Fee
- Domestic vs. Foreign Facility Fees: Foreign sites generally incur slightly higher fees due to inspection overheads
- Note: Not all self-identified sites are required to pay fees — e.g., certain BE/BA sites and testing labs may be exempt. Cliniexpertshelps assess your fee applicability and ensures you’re not overpaying.
Validity
GDUFA self-identification is valid for one FDA fiscal year:
October 1 – September 30.
- Facilities must re-submit their information annually to remain compliant.
- Any changes in ownership, site status, or activity must be updated promptly.
Frequently Asked Questions(FAQs)
Who is required to complete GDUFA self-identification?
Any facility involved in the manufacturing, packaging, labeling, testing, or clinical evaluation of human generic drugs — including API and FDF sites — must self-identify with the FDA annually. This includes both domestic and foreign facilities referenced in an ANDA.
When is the GDUFA self-identification period and deadline?
The self-identification window runs from May 1 to June 30 each year, ahead of the FDA’s fiscal year starting October 1. Timely submission is required to avoid regulatory delays or penalties.
What documents are needed for GDUFA self-identification?
Facilities must provide details such as a valid DUNS number, physical site address, ownership information, establishment type, and contact person authorization. Additional data may be needed depending on facility activity.
What are the consequences of not self-identifying with the FDA?
Failure to self-identify can result in FDA refusing to accept ANDA submissions that list your facility. It may also delay inspections or lead to facility exclusion from regulatory filings — impacting business continuity.
Do all self-identified facilities have to pay GDUFA fees?
No. While FDF and API manufacturing facilities are subject to annual GDUFA facility fees, certain sites (e.g., bioequivalence study centers or testing labs) may be exempt. Cliniexperts helps assess fee applicability during the compliance process.
